North Carolina' s Parion Sciences and Gilead have initiated a Phase I clinical trial of GS9411, and experimental therapy designed to increase airway hydration for the treatment of pulmonary disease. Parion will get a $5 million milestone payment from Gilead. Release
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
 |
Click here to get the FierceBiotech email newsletter for FREE!
Be the first to comment